441 related articles for article (PubMed ID: 16351642)
1. High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
Wolberg AS; Allen GA; Monroe DM; Hedner U; Roberts HR; Hoffman M
Br J Haematol; 2005 Dec; 131(5):645-55. PubMed ID: 16351642
[TBL] [Abstract][Full Text] [Related]
2. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
3. General haemostatic agents--fact or fiction?
Hedner U
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots.
Dargaud Y; Prevost C; Lienhart A; Claude Bordet J; Negrier C
Haemophilia; 2011 Nov; 17(6):957-61. PubMed ID: 21453422
[TBL] [Abstract][Full Text] [Related]
5. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.
He S; Blombäck M; Jacobsson Ekman G; Hedner U
J Thromb Haemost; 2003 Jun; 1(6):1215-9. PubMed ID: 12871322
[TBL] [Abstract][Full Text] [Related]
6. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.
von dem Borne PA; Cox LM; Bouma BN
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):251-7. PubMed ID: 16651866
[TBL] [Abstract][Full Text] [Related]
7. A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation.
Campbell RA; Fischer TH; Wolberg AS
Br J Haematol; 2007 Jul; 138(1):82-93. PubMed ID: 17555451
[TBL] [Abstract][Full Text] [Related]
8. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
9. Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.
Bakhtiari K; Kamphuisen PW; Mancuso ME; Hamulyak K; Schutgens RE; Santagostino E; Meijers JC
Br J Haematol; 2013 Sep; 162(6):827-35. PubMed ID: 23889493
[TBL] [Abstract][Full Text] [Related]
10. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
11. Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation.
Lisman T; Leebeek FW; Meijer K; Van Der Meer J; Nieuwenhuis HK; De Groot PG
Hepatology; 2002 Mar; 35(3):616-21. PubMed ID: 11870375
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation.
Li R; Panckeri KA; Fogarty PF; Cuker A; Diamond SL
Haemophilia; 2017 Sep; 23(5):759-768. PubMed ID: 28475272
[TBL] [Abstract][Full Text] [Related]
13. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA
Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408
[TBL] [Abstract][Full Text] [Related]
14. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.
Gray LD; Hussey MA; Larson BM; Machlus KR; Campbell RA; Koch G; Ezban M; Hedner U; Wolberg AS
Thromb Res; 2011 Dec; 128(6):570-6. PubMed ID: 21561645
[TBL] [Abstract][Full Text] [Related]
15. The thrombin activation pathway modulates the assembly, structure and lysis of human plasma clots in vitro.
Torbet J
Thromb Haemost; 1995 May; 73(5):785-92. PubMed ID: 7482404
[TBL] [Abstract][Full Text] [Related]
16. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
Aljamali MN; Kjalke M; Hedner U; Ezban M; Tranholm M
Haemophilia; 2009 Nov; 15(6):1318-26. PubMed ID: 19659796
[TBL] [Abstract][Full Text] [Related]
17. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients.
Brophy DF; Martin EJ; Nolte ME; Kuhn JG; Carr ME
Haemophilia; 2007 Sep; 13(5):533-41. PubMed ID: 17880440
[TBL] [Abstract][Full Text] [Related]
18. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion.
Carr ME; Martin EJ; Kuhn JG; Seremetis SV
Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776
[TBL] [Abstract][Full Text] [Related]
19. Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation.
Taketomi T; Szlam F; Bader SO; Sheppard CA; Levy JH; Tanaka KA
Blood Coagul Fibrinolysis; 2008 Mar; 19(2):135-41. PubMed ID: 18277134
[TBL] [Abstract][Full Text] [Related]
20. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
